Developing oncolytic Herpes simplex virus type 1 through UL39 knockout by CRISPR-Cas9

OBJECTIVE(S): Oncolytic Herpes simplex virus type 1 (HSV-1) has emerged as a promising strategy for cancer therapy. However, development of novel oncolytic mutants has remained a major challenge owing to low efficiency of conventional genome editing methods. Recently, CRISPR-Cas9 has revolutionized...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebrahimi, Saeedeh, Makvandi, Manoochehr, Abbasi, Samaneh, Azadmanesh, Kayhan, Teimoori, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mashhad University of Medical Sciences 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395182/
https://www.ncbi.nlm.nih.gov/pubmed/32774817
http://dx.doi.org/10.22038/ijbms.2020.43864.10286

Ejemplares similares

Ejemplares similares